Medtronic (MDT) Set to Announce Earnings on Tuesday

Medtronic (NYSE:MDT) is scheduled to announce its earnings results before the market opens on Tuesday, November 19th. Analysts expect Medtronic to post earnings of $1.24 per share for the quarter. Medtronic has set its FY25 guidance at $5.42-5.50 EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, August 20th. The medical technology company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. Medtronic had a net margin of 12.06% and a return on equity of 13.68%. The business had revenue of $7.97 billion for the quarter, compared to analyst estimates of $7.90 billion. During the same quarter in the previous year, the firm posted $1.20 earnings per share. Medtronic’s revenue was up 3.4% compared to the same quarter last year. On average, analysts expect Medtronic to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Medtronic Price Performance

Shares of Medtronic stock opened at $87.53 on Monday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.13 and a quick ratio of 1.61. The company has a market cap of $112.25 billion, a PE ratio of 29.57, a price-to-earnings-growth ratio of 2.50 and a beta of 0.84. The firm has a fifty day moving average price of $89.48 and a two-hundred day moving average price of $84.77. Medtronic has a fifty-two week low of $74.20 and a fifty-two week high of $92.68.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on MDT shares. Daiwa America upgraded shares of Medtronic to a “strong-buy” rating in a research note on Friday, August 23rd. Piper Sandler raised their price objective on Medtronic from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. Truist Financial boosted their price objective on Medtronic from $90.00 to $93.00 and gave the company a “hold” rating in a research report on Monday, October 14th. Stifel Nicolaus raised their target price on Medtronic from $85.00 to $87.00 and gave the stock a “hold” rating in a research report on Wednesday, August 21st. Finally, Wells Fargo & Company boosted their price target on shares of Medtronic from $105.00 to $106.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Medtronic presently has an average rating of “Hold” and an average price target of $95.80.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.